ClinicalTrials.gg
RecruitingNCT06857227Updated Apr 15, 2025

A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis

A Phase 1 interventional study of GNC-038 and Placebo in Rheumatoid Arthritis, sponsored by Sichuan Baili Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-15.

Sponsored by Sichuan Baili Pharmaceutical Co., Ltd. (part of Sichuan Biokin Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 249 studies in Arthritis, Rheumatoid with a site in China — 63 open to participants now, 72 under way, 3 of them phase 3. Arthritis, Rheumatoid · China.

Planned enrollment
157th of 217
54 · median 134
Started
2025
with 34 others
Phase 1
54 of 249
20 open now
Primary completion
2027-12
later than 49 of 71 live
Registered
194th of 249
by date

Among the 249 studies in Arthritis, Rheumatoid with a site in China, this one is the 157th largest by planned enrollment of the 217 interventional ones that give a count, is one of 35 that started in 2025, is one of 54 in phase 1, reaches primary completion later than 49 of the 71 other live ones, and was the 194th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

63 of the 249 studies in Arthritis, Rheumatoid with a site in China are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies in Arthritis, Rheumatoid with a site in China, or all of them as a file.
02

Study summary

This study is a randomized controlled phase I clinical study with safety, efficacy, and pharmacokinetic/pharmacodynamic characteristics in patients with rheumatoid arthritis.

Read the detailed description

This study is divided into a phase Ia study and a phase Ib study. The phase Ib study has a randomized controlled design with a placebo control group. The phase Ia study has a single-arm design, and the phase Ib study will be carried out on the basis of the Phase Ia study.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects can understand the form, voluntarily participate in and sign the informed consent form;
  2. No gender limit;
  3. Age: ≥18 years old and ≤75 years old;
  4. greater than 6 months;
  5. Patients diagnosed with rheumatoid arthritis according to 1987 or 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria;
  6. Patients were moderately to severely active RA at the time of screening;
  7. A stable standard-of-care regimen was maintained for at least 30 days before the first dose;
  8. Previous treatment with antirheumatic drugs other than MTX: Leflunomide should be discontinued at least 8 weeks before the start of study treatment or cholestyramine should be used for 14 days;
  9. Erythrocyte sedimentation rate (ESR) > 28mm/hr or C-reactive protein (CRP) > 10mg/L;
  10. Positive rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies;
  11. There were CD19+ B cells in the peripheral blood of the patient;
  12. Diagnosis of rheumatoid arthritis (RA) more than 6 months;
  13. The organ function level before the first administration met the requirements;
  14. Fertile female subjects or male subjects with fertile partners must use highly effective from 7 days before the first dose until 24 weeks after the termination of treatment and should commit not to donate eggs (eggs, oocytes)/sperm for assisted reproduction for 1 year after the last study treatment. Female subjects of must have a negative serum/urine pregnancy test within 7 days before the first dose;
  15. Participants were able and willing to comply with protocol-specified visits, treatment plans, laboratory tests, and other study-related procedures.

Exclusion criteria

Exclusion Criteria:

  1. Confirmed diagnosis of another rheumatic disease;
  2. B cell-targeted therapy agents administered within 6 months before GNC-038 treatment;
  3. Received CAR-T therapy within 6 months before GNC-038 treatment;
  4. Use of anti-TNF drugs within 8 weeks before administration;
  5. Use of any JAK inhibitor within 2 weeks before dosing;
  6. Antimalarial drugs, sulfasalazine, penicillamine, etc. were used within 4 weeks before the drug administration;
  7. Use of phytochemicals within 4 weeks before administration;
  8. The use of other biological agents or other non-B cell depleting clinical drugs before drug administration did not exceed 5 half-lives;
  9. Received an intra-articular injection within 4 weeks before study entry;
  10. Receipt of any investigational drug within 28 days before dose or within 5 half-lives of the investigational drug;
  11. ACR functional class IV or bedridden/wheelchair-bound;
  12. History of major organ transplantation or hematopoietic stem cell/bone marrow transplantation;
  13. Presence of: 1) active at screening; 2) or infection; 3) syphilis infection;
  14. A history of any cardiovascular disease described in the protocol within 6 months before screening;
  15. Poorly controlled hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg);
  16. Prolonged at rest (QTcf > 450 msec in men or > 470 msec in women);
  17. A history of ≥ grade 2 bleeding within 30 days before screening or the need for long-term continuous anticoagulant therapy;
  18. Patients with a history of allergy to recombinant humanized antibodies or to any of the of GNC-038;
  19. Women who are pregnant or breastfeeding;
  20. Having a history or evidence of suicidal thoughts within 6 months before signing ICF, which is considered by the researcher to be a significant risk of suicide;
  21. Diagnosed with malignant tumor within 5 years before signing ICF;
  22. Other situations of poor compliance, unwillingness or inability to comply with the study protocol as judged by the investigator;
  23. History of splenectomy;
  24. Investigators considered a history of alcohol or drug abuse in the 12 months before screening;
  25. Any active infection requiring systemic antibiotic treatment within 2 weeks before or during screening;
  26. A history of severe and/or disseminated viral infection;
  27. Active M. tuberculosis infection may be present.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    GNC-038

    Participants receive GNC-038 in the first cycle. Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

    Drug: GNC-038

  • Placebo comparator
    Placebo

    The control group will be set up in phase Ib, participants will receive placebo.

    Drug: Placebo

Interventions

  • Administration by intravenous infusion. Once a week (IV, QW), twice in total.

  • DrugPlacebo

    The control group will be set up in phase Ib, and an appropriate dose will be selected based on phase Ia data.

06

What researchers measure

Primary outcomes

  1. Phase Ia: Dose limiting toxicity (DLT)

    DLTs are assessed according to NCI-CTCAE v5.0 during the first cycle and defined as occurrence of any of the toxicities in DLT definition if judged by the investigator to be possibly, probably or definitely related to study drug administration.

    Time frame: Up to approximately 28 days

  2. Phase Ia: Maximum tolerated dose (MTD) or Maximum administered dose (MAD)

    MTD is defined as the highest dose level at which no more than 1 in 6 participants experienced a DLT during the first cycle.

    Time frame: Up to approximately 28 days

  3. Phase Ia: Treatment-Emergent Adverse Event (TEAE)

    TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of GNC-038. The type, frequency and severity of TEAE will be evaluated during the treatment of GNC-038.

    Time frame: Up to approximately 24 months

  4. Phase Ia: Cmax

    Maximum serum concentration (Cmax) of GNC-038 will be investigated.

    Time frame: Up to approximately 24 months

  5. Phase Ia: Tmax

    Time to maximum serum concentration (Tmax) of GNC-038 will be investigated.

    Time frame: Up to approximately 24 months

  6. Phase Ia: T1/2

    Half-life (T1/2) of GNC-038 will be investigated.

    Time frame: Up to approximately 24 months

  7. Phase Ia: AUC0-t

    AUC0-t is defined as area under the serum concentration-time curve from time 0 to the time of the last measurable concentration.

    Time frame: Up to approximately 24 months

  8. Phase Ia: CL (Clearance)

    CL in the serum of GNC-038 per unit of time will be investigated.

    Time frame: Up to approximately 24 months

  9. Phase Ib: Recommended Phase II Dose (RP2D)

    The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of GNC-038.

    Time frame: Up to approximately 24 months

  10. Phase Ib: Proportion of patients meeting ACR20 remission criteria

    Proportion of patients meeting ACR20 remission criteria will be investigated.

    Time frame: Up to approximately 24 months

Secondary outcomes

  1. Anti-drug antibody (ADA)

    Frequency of anti-GNC-038 antibody (ADA) will be investigated.

    Time frame: Up to approximately 24 months

  2. Phase Ia: Receptor Occupancy (RO)

    Receptor Occupancy (RO) will be investigated.

    Time frame: Up to approximately 24 months

  3. Phase Ib: Change from baseline in quality of life (SF-36)

    Change from baseline in quality of life (SF-36) will be investigated.

    Time frame: Up to approximately 24 months

  4. Phase Ib: Change from baseline in DAS28 CRP

    Change from baseline in DAS28 CRP will be investigated.

    Time frame: Up to approximately 24 months

  5. Phase Ib: Proportion of patients meeting ACR50 response criteria

    Proportion of patients meeting ACR50 response criteria will be investigated.

    Time frame: Up to approximately 24 months

  6. Phase Ib: Proportion of patients meeting ACR70 response criteria

    Proportion of patients meeting ACR70 response criteria will be investigated.

    Time frame: Up to approximately 24 months

07

Study locations

1 of 1 sites recruiting
  • Renji Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai, China
    Recruiting
    • Shuang Ye · Contact
    • Shuang Ye · Principal investigator
    • Qiong Fu · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2027, 33 months after the start.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 33 months is above that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2025
First posted
Mar 4, 2025
StartActual
Mar 17, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Apr 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06857227
Collaborators
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Mar 4, 2025
Start date
Mar 17, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Apr 15, 2025

Study contacts

Sa Xiao, PHD
Contact
xiaosa@baili-pharm.com
15013238943

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emfizatamab

Start the discussion